Rapid aneuploidy detection with multiplex ligation-dependent probe amplification: a prospective study of 4000 amniotic fluid samples.
The introduction of prenatal screening requires rapid high-throughput diagnosis of common aneuploidies. Multiplex ligation-dependent probe amplification (MLPA) allows for quick, easily automated multiplex testing of these aneuploidies in one polymerase chain reaction. We performed a large prospective study using MLPA on 4000 amniotic fluid (AF) samples including all indications and compared its value to karyotyping and fluorescence in situ hybridization (FISH). MLPA can reliably determine common aneuploidies with 100% sensitivity and 100% specificity. Moreover, some mosaic cases and structural chromosome aberrations were detected as well. In cases of a male fetus, triploidies can be detected by an aberrant pattern of probe signals, which mimics maternal cell contamination (MCC). Macroscopic blood contamination was encountered in 3.2% of the AF samples. In 20% of these samples, an MLPA pattern was found consistent with MCC, although there were no false negatives of the most common aneuploidies. As the vast majority of inconclusive results (1.7%) is due to potential MCC, we designed a protocol in which we determine whether MLPA can be performed on blood-contaminated AF samples by testing if blood is of fetal origin. Then, the number of inconclusive results could be theoretically reduced to 0.05%. We propose an alternative interpretation of relative probe signals for rapid aneuploidy diagnosis (RAD). We discuss the value of MLPA for the detection of (submicroscopic) structural chromosome anomalies. MLPA is a reliable method that can replace FISH and could be used as a stand-alone test for RAD instead of karyotyping.
Van Opstal
Diane
D
Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
Boter
Marjan
M
de Jong
Danielle
D
van den Berg
Cardi
C
Brüggenwirth
Hennie T
HT
Wildschut
Hajo I J
HI
de Klein
Annelies
A
Galjaard
Robert-Jan H
RJ
D000649:Amniocentesis / Q000379:methods; D000653:Amniotic Fluid; D000782:Aneuploidy; D005188:False Negative Reactions; D005260:Female; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D008297:Male; D015336:Molecular Probe Techniques; D009030:Mosaicism; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D011247:Pregnancy; D012680:Sensitivity and Specificity; D014314:Trisomy / Q000175:diagnosis
Nucleic Acids Res. 2002 Jun 15;30(12):e57
12060695
J Med Genet. 2005 Jan;42(1):38-44
15635073
Prenat Diagn. 2003 Mar;23(3):201-10
12627420
Prenat Diagn. 2005 Nov;25(11):1032-9
16231311
Am J Med Genet C Semin Med Genet. 2007 Feb 15;145C(1):87-98
17290441
Am J Hum Genet. 1977 Jan;29(1):94-7
835578
Lancet. 1993 Sep 25;342(8874):802
8103886
Hum Reprod. 2007 Apr;22(4):1037-41
17272360
Prenat Diagn. 2005 Jan;25(1):79-83
15662689
Reproduction. 2003 Sep;126(3):279-97
12968936
J Med Genet. 2003 Dec;40(12):907-12
14684689
BJOG. 2005 Oct;112(10):1369-75
16167939
Clin Chem. 1995 Dec;41(12 Pt 1):1778-80
7497623
Am J Med Genet. 1983 Jun;15(2):297-305
6349361
Prenat Diagn. 2002 Jan;22(1):29-33
11810646
Prenat Diagn. 1996 Jan;16(1):49-54
8821852
Eur J Hum Genet. 2004 Nov;12(11):907-15
15292918
Eur J Hum Genet. 2005 Feb;13(2):171-5
15483643
Lancet. 2005 Jul 9-15;366(9480):97-8
16005312
Prenat Diagn. 1995 Aug;15(8):705-11
7479588
Prenat Diagn. 2001 Feb;21(2):75-80
11241529
Ann Genet. 2001 Oct-Dec;44(4):209-17
11755107
Ultrasound Obstet Gynecol. 2007 Sep;30(3):247-51
17721912
BMJ. 2006 Feb 25;332(7539):452-5
16476673
Lancet. 2005 Jul 9-15;366(9480):123-8
16005334
Mol Hum Reprod. 2004 Nov;10(11):839-46
15361554
Obstet Gynecol. 1998 Oct;92(4 Pt 1):551-6
9764627
Health Technol Assess. 2003;7(10):1-146
12773259